Some proteins such as β-catenin may have mutations in the GSK-3β phosphorylation sites in certain cancer cells, which prevent GSK-3β-dependent phosphorylation and lead to constitutive activation of the Wnt/β-catenin pathway and contribute to cancer development. This evidence concerns the gene GSK3B and cancer.